Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors

Patricia M. LoRusso, Antonio Jimeno, Grace Dy, Alex Adjei, Jordan Berlin, Lawrence Leichman, Jennifer A. Low, Dawn Colburn, Ilsung Chang, Sravanthi Cheeti, Jin Y. Jin, Richard A. Graham

Research output: Contribution to journalArticle

72 Scopus citations

Abstract

Purpose: This study was designed to evaluate whether less frequent dosing [three times per week (TIW) or once weekly (QW)] of 150 mg vismodegib following a loading dose [150 mg once daily (QD) for 11 days] would result in similar safety, tolerability, and steady-state levels of total and unbound vismodegib as continuous QD dosing. Experimental Design: Sixty-seven patients with advanced solid tumors were stratified by baseline plasma alpha 1-acid glycoprotein (AAG) levels and randomized to one of three vismodegib 150 mg regimens:QD (n = 23), TIW (n = 22), orQW(n = 22) for up to 42 days after an 11-day loading phase (150 mgQD). Total and unbound (dialyzed) plasma vismodegib concentrations were determined by LC-MS/MS. Results: The most frequently reported adverse events were consistent with those in prior monotherapy trials, with similar incidence and severity regardless of dosing schedule. After the 150 mg QD loading phase, a concentration-dependent change in protein binding (3-fold increase in vismodegib fraction unbound) was observed at steady state compared with single dose. Mean total and unbound vismodegib steady-state concentrations were lower after TIW and QW than QD dosing, with an average intrasubject decrease of 50% and 80%, respectively, for unbound drug. Mechanism-based PK model simulations accurately and prospectively predicted the PK results. Conclusions: Vismodegib 150 mg TIW or QW failed to achieve unbound plasma concentrations previously associated with efficacy in patients with advanced basal cell carcinoma and medulloblastoma, even after a QD loading dose period. The 150 mg QD regimen is appropriate for vismodegib based on its clinical activity, tolerability, and favorable unbound concentrations.

Original languageEnglish (US)
Pages (from-to)5774-5782
Number of pages9
JournalClinical Cancer Research
Volume17
Issue number17
DOIs
StatePublished - Sep 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors'. Together they form a unique fingerprint.

  • Cite this

    LoRusso, P. M., Jimeno, A., Dy, G., Adjei, A., Berlin, J., Leichman, L., Low, J. A., Colburn, D., Chang, I., Cheeti, S., Jin, J. Y., & Graham, R. A. (2011). Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clinical Cancer Research, 17(17), 5774-5782. https://doi.org/10.1158/1078-0432.CCR-11-0972